Low expression levels of microRNA-124-5p correlated with poor prognosis in colorectal cancer via targeting of SMC4

Cancer Medicine

Volumn 3, Issue 6, 2014, Pages 1544-1552

  Jinushi, Takafumi ^a,b   Shibayama, Yoshihiko ^a   Kinoshita, Ichiro ^c   Oizumi, Satoshi ^c   Jinushi, Masahisa ^d   Aota, Tadahiro ^b   Takahashi, Toshiyuki ^b   Horita, Shoichi ^b   Dosaka Akita, Hirotoshi ^c   Iseki, Ken ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b Hokkaido Gastroenterological Hospital   (Japan)

^c HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d Institute for Genetic Medicine   (Japan)

Author keywords

Colorectal cancer; EZH2; MFGE8; MiR 124 5p; MiR 26a; SMC4

Indexed keywords

ADENOSINE TRIPHOSPHATASE; EZH2 PROTEIN, HUMAN; MEMBRANE ANTIGEN; MESSENGER RNA; MFGE8 PROTEIN, HUMAN; MICRORNA; MILK PROTEIN; MIRN124 MICRORNA, HUMAN; NONHISTONE PROTEIN; PARAFFIN; POLYCOMB REPRESSIVE COMPLEX 2; SMC4 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; BIOSYNTHESIS; BLOOD; COLORECTAL TUMOR; FEMALE; GENETIC TRANSFECTION; GENETICS; HUMAN; MALE; METABOLISM; MIDDLE AGED; PROGNOSIS; VERY ELDERLY;

ADENOSINE TRIPHOSPHATASES; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, SURFACE; BIOMARKERS, TUMOR; CHROMOSOMAL PROTEINS, NON-HISTONE; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MICRORNAS; MIDDLE AGED; MILK PROTEINS; PARAFFIN EMBEDDING; POLYCOMB REPRESSIVE COMPLEX 2; PROGNOSIS; RNA, MESSENGER; TRANSFECTION;

EID: 84990927280     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.309     Document Type: Article

References (37)

1. Gellad, Z. F., and D. Provenzale. 2010. Colorectal cancer: national and international perspective on the burden of disease and public health impact. Gastroenterology 138:2177-2190.
2. Siegel, R., J. Ma, Z. Zou, and A. Jemal. 2014. Cancer statistics, 2014. CA Cancer J. Clin. 64:9-29.
3. Stricker, T., D. V. Catenacci, and T. Y. Seiwert. 2011. Molecular profiling of cancer-the future of personalized cancer medicine: a primer on cancer biology and the tools necessary to bring molecular testing to the clinic. Semin. Oncol. 38:173-185.
4. Kikuchi, J., I. Kinoshita, Y. Shimizu, E. Kikuchi, J. Konishi, S. Oizumi, et al. 2010. Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance. Cancer 116:3015-3024.
5. Tan, J. Z., Y. Yan, X. X. Wang, Y. Jiang, and H. E. Xu. 2014. EZH2: biology, disease, and structure-based drug discovery. Acta Pharmacol. Sin. 35:161-174.
6. Jinushi, M., S. Chiba, H. Yoshiyama, K. Masutomi, I. Kinoshita, H. Dosaka-Akita, et al. 2011. Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem/initiating cells. Proc. Natl. Acad. Sci. USA 108:12425-12430.
7. Aziz, M., A. Jacob, A. Matsuda, and P. Wang. 2011. Review: milk fat globule-EGF factor 8 expression, function and plausible signal transduction in resolving inflammation. Apoptosis 16:1077-1086.
8. Esquela-Kerscher, A., and F. J. Slack. 2006. Oncomirs-microRNAs with a role in cancer. Nat. Rev. Cancer 6:259-269.
9. Mitchell, P. S., R. K. Parkin, E. M. Kroh, B. R. Fritz, S. K. Wyman, E. L. Pogosova-Agadjanyan, et al. 2008. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. USA 105:10513-10518.
10. Schetter, A. J., and C. C. Harris. 2009. Plasma microRNAs: a potential biomarker for colorectal cancer? Gut 58:1318-1319.
11. Su, H., J. R. Yang, T. Xu, J. Huang, L. Xu, Y. Yuan, et al. 2009. MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res. 69:1135-1142.
12. Xu, L., S. Beckebaum, S. Iacob, G. Wu, G. M. Kaiser, A. Radtke, et al. 2014. MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity. J. Hepatol. 60:590-598.
13. Cho, H. M., H. S. Jeon, S. Y. Lee, K. J. Jeong, S. Y. Park, H. Y. Lee, et al. 2011. microRNA-101 inhibits lung cancer invasion through the regulation of enhancer of zeste homolog 2. Exp. Ther. Med. 2:963-967.
14. Song, Q. C., Z. B. Shi, Y. T. Zhang, L. Ji, K. Z. Wang, D. P. Duan, et al. 2014. Downregulation of microRNA-26a is associated with metastatic potential and the poor prognosis of osteosarcoma patients. Oncol. Rep. 31:1263-1270.
15. Betel, D., M. Wilson, A. Gabow, D. S. Marks, and C. Sander. 2008. The microRNA.org resource: targets and expression. Nucleic Acids Res. 36:D149-D153.
16. Qian, J., B. Jiang, M. Li, J. Chen, and M. Fang. 2013. Prognostic significance of microRNA-16 expression in human colorectal cancer. World J. Surg. 37:2944-2949.
17. Fanini, F., I. Vannini, D. Amadori, and M. Fabbri. 2011. Clinical implications of microRNAs in lung cancer. Semin. Oncol. 38:776-780.
18. Ichikawa, T., F. Sato, K. Terasawa, S. Tsuchiya, M. Toi, G. Tsujimoto, et al. 2012. Trastuzumab produces therapeutic actions by upregulating miR-26a and miR-30b in breast cancer cells. PLoS ONE 7:e31422.
19. Heckmann, D., P. Maier, S. Laufs, L. Li, J. P. Sleeman, M. J. Trunk, et al. 2014. The disparate twins: a comparative study of CXCR4 and CXCR7 in SDF-1alpha-induced gene expression, invasion and chemosensitivity of colon cancer. Clin. Cancer Res. 20:604-616.
20. Lin, Q., W. Mao, Y. Shu, F. Lin, S. Liu, H. Shen, et al. 2012. A cluster of specified microRNAs in peripheral blood as biomarkers for metastatic non-small-cell lung cancer by stem-loop RT-PCR. J. Cancer Res. Clin. Oncol. 138:85-93.
21. Anwar, S. L., C. Albat, T. Krech, B. Hasemeier, E. Schipper, N. Schweitzer, et al. 2013. Concordant hypermethylation of intergenic microRNA genes in human hepatocellular carcinoma as new diagnostic and prognostic marker. Int. J. Cancer 133:660-670.
22. Skog, J., T. Würdinger, S. van Rijn, D. H. Meijer, L. Gainche, M. Sena-Esteves, et al. 2008. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat. Cell Biol. 10:1470-1476.
23. Zhou, B., T. Yuan, M. Liu, H. Liu, J. Xie, Y. Shen, et al. 2012. Overexpression of the structural maintenance of chromosome 4 protein is associated with tumor de-differentiation, advanced stage and vascular invasion of primary liver cancer. Oncol. Rep. 28:1263-1268.
24. Watanabe, T., M. Itabashi, Y. Shimada, S. Tanaka, Y. Ito, Y. Ajioka, et al. 2012. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer. Int. J. Clin. Oncol. 17:1-29.
25. Fukao, T., Y. Fukuda, K. Kiga, J. Sharif, K. Hino, Y. Enomoto, et al. 2007. An evolutionarily conserved mechanism for microRNA-223 expression revealed by microRNA gene profiling. Cell 129:617-631.
26. Dalle Carbonare, L., A. Frigo, G. Francia, M. V. Davi, L. Donatelli, C. Stranieri, et al. 2012. Runx2 mRNA expression in the tissue, serum, and circulating non-hematopoietic cells of patients with thyroid cancer. J. Clin. Endocrinol. Metab. 97:E1249-E1256.
27. Baldus, C. D., S. M. Tanner, A. S. Ruppert, S. P. Whitman, K. J. Archer, G. Marcucci, et al. 2003. BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study. Blood 102:1613-1618.
28. Shibayama, Y., K. Nakano, H. Maeda, M. Taguchi, R. Ikeda, M. Sugawara, et al. 2011. Multidrug resistance protein 2 implicates anticancer drug-resistance to sorafenib. Biol. Pharm. Bull. 34:433-435.
29. Chang, C. J., and M. C. Hung. 2012. The role of EZH2 in tumour progression. Br. J. Cancer 106:243-247.
30. Jinushi, M., Y. Nakazaki, D. R. Carrasco, D. Draganov, N. Souders, M. Johnson, et al. 2008. Milk fat globule EGF-8 promotes melanoma progression through coordinated Akt and twist signaling in the tumor microenvironment. Cancer Res. 68:8889-8898.
31. Tibaldi, L., S. Leyman, A. Nicolas, S. Notebaert, M. Dewulf, T. H. Ngo, et al. 2013. New blocking antibodies impede adhesion, migration and survival of ovarian cancer cells, highlighting MFGE8 as a potential therapeutic target of human ovarian carcinoma. PLoS ONE 8:e72708.
32. Oba, J., Y. Moroi, T. Nakahara, T. Abe, A. Hagihara, and M. Furue. 2011. Expression of milk fat globule epidermal growth factor-VIII may be an indicator of poor prognosis in malignant melanoma. Br. J. Dermatol. 165:506-512.
33. Wang, M. J., Y. Li, R. Wang, C. Wang, Y. Y. Yu, L. Yang, et al. 2013. Downregulation of microRNA-124 is an independent prognostic factor in patients with colorectal cancer. Int. J. Colorectal Dis. 28:183-189.
34. Zhai, L., H. Wang, W. Tang, W. Liu, S. Hao, and X. Zeng. 2011. Disturbance in function and expression of condensin affects chromosome compaction in HeLa cells. Cell Biol. Int. 35:735-740.
35. Ono, T., A. Losada, M. Hirano, M. P. Myers, A. F. Neuwald, and T. Hirano. 2003. Differential contributions of condensin I and condensin II to mitotic chromosome architecture in vertebrate cells. Cell 115:109-121.
36. Qian, X., P. Zhao, W. Li, Z. M. Shi, L. Wang, Q. Xu, et al. 2013. MicroRNA-26a promotes tumor growth and angiogenesis in glioma by directly targeting prohibitin. CNS Neurosci. Ther. 19:804-812.
37. Zhang, J., C. Han, and T. Wu. 2012. MicroRNA-26a promotes cholangiocarcinoma growth by activating beta-catenin. Gastroenterology 143:e248.